Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

House GOP Seeks Stopgap Bill to Prevent Government Shutdown Amid Trump Meetings with Holdouts

March 5, 2025

Trump Urges Republican Senators to Oppose Tariff Resolution Vote

April 2, 2025

Trump Proposes Public Offering for Fannie Mae and Freddie Mac: Implications for Homebuyers and Investors

May 24, 2025

Trump Claims Bond Market Turmoil Had No Impact on Tariff Delay: ‘I Wasn’t Worried’

April 25, 2025

Trump Meets Ukraine’s President Zelenskyy Before Pope Francis’ Funeral, White House Reports

April 26, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • Trump’s Proposed Plan for Gaza Peace: Key Details Unveiled
  • Arizona Woman Accused of Aiding North Korean Workers to Breach US Companies
  • El Salvador Man Sentenced to 30 Years for Rape of 11-Year-Old in Virginia Beach
  • Germany Anticipates Modest Growth with Merz’s €500 Billion Overhaul Plan
  • Man Charged with Arson in Pacific Palisades Fire
  • AKP Chairman Resigns Amid Political Turmoil
  • Workplace Deaths Rise: 206 Workers Killed in September Across Construction and Agriculture
  • Israel and Hamas Agree on Hostage Release and Partial Troop Withdrawal
  • Increasing Cannabis Use Among Seniors: Reasons and Trends
  • AI-Driven Curriculum Replaces Teachers at $40,000-a-Year School
  • Dolly Parton Assures Fans She Is Not Dying After Sister’s Prayer Request
  • Domino’s Unveils First Major Redesign in 13 Years
  • Manchester Synagogue Attacker Swears Allegiance to Islamic State Prior to Assault
  • Senate Fails to Reach Agreement on Day 8 of Government Shutdown
  • Auto Industry Faces Turmoil as EU Implements New Steel Tariffs
  • FOMC Predicts Two Additional Rate Cuts by End of 2025
  • Air Traffic Control Shortages Contribute to U.S. Flight Delays, FAA Reports
  • COVID Mask Mandates Reinstated in Blue-State County Due to Increased Risk
  • Boston Pro-Palestinian Protest Escalates into Violent Riot, 13 Arrested
  • Israel Commemorates Two Years Since Hamas Attack Amid Ongoing Gaza War Reflections
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Wednesday, October 8
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Money Watch » FDA Approves Twice-Yearly Injection of HIV Prevention Drug Lenacapavir
FDA Approves Twice-Yearly Injection of HIV Prevention Drug Lenacapavir

FDA Approves Twice-Yearly Injection of HIV Prevention Drug Lenacapavir

News EditorBy News EditorJune 22, 2025 Money Watch 4 Mins Read

The U.S. Food and Drug Administration (FDA) has recently sanctioned lenacapavir, marketed as Yeztugo, as a bi-annual injection aimed at preventing HIV infection. The approval was predicated on compelling clinical trial results, indicating a remarkable 99.9% efficacy in keeping participants HIV-negative. Gilead Sciences, the manufacturer, heralded this milestone as a transformative step in combating the HIV epidemic, even as concerns loom regarding the halt of funding for HIV vaccine research.

Article Subheadings
1) FDA Approval of Lenacapavir
2) Implications for the HIV Epidemic
3) Vaccine Research Under Threat
4) Expert Insights on Vaccine Development
5) Broader Context of HIV Research Funding

FDA Approval of Lenacapavir

On Wednesday, the FDA granted approval for lenacapavir, a drug developed by Gilead Sciences, as a preventive treatment against HIV. This prescription medication, administered as an injection twice a year, is seen as a significant breakthrough in the fight against the HIV epidemic. Clinical trials supporting the approval demonstrated that 99.9% of participants who received lenacapavir remained HIV negative. The approval was influenced by robust data, emphasizing its potency and the potential to dramatically reduce new HIV infections.

Implications for the HIV Epidemic

According to recent findings from the Centers for Disease Control and Prevention (CDC), the United States recorded an estimated 31,800 new HIV infections in 2022—a worrying statistic that underscores the ongoing challenge posed by this virus. The approval of lenacapavir is anticipated to be a game-changer, with health officials calling it a major step toward controlling transmission rates. Daniel O’Day, Gilead’s CEO, characterized the decision as a “milestone moment in the decades-long fight against HIV.” His comments underscore the transformative potential of this new drug in shifting the narrative on HIV prevention.

Vaccine Research Under Threat

Despite the remarkable advancement marked by the approval of lenacapavir, there are escalating concerns about the future of HIV vaccine research. The current administration has proposed significant funding cuts to various HIV vaccine initiatives, arguing that available treatments, including lenacapavir, are sufficient. Critics of this decision contend that halting support for vaccine research is perilous, raising alarms about the prospect of a long-term solution to HIV prevention.

Expert Insights on Vaccine Development

Experts in the field have expressed mixed feelings about the approval of lenacapavir amid funding cuts to vaccine research. Dr. Barton Ford Haynes, the director of the Duke Human Vaccine Institute, described lenacapavir as a “wonderful development,” yet emphasized that the pursuit of an HIV vaccine remains critically important.

“This is a terrible time to cut it off. We’re beginning to get close. We’re getting good results out of clinical trials,”

said Dennis Burton, an immunology professor at Scripps Research. His sentiments reflect the urgency for continued investment in vaccine research to complement newly approved treatments.

Broader Context of HIV Research Funding

The decision to cut funding for HIV vaccine research could have far-reaching implications, hindering progress potentially for a decade. Dennis Burton cautioned that various ongoing experiments and studies could be disrupted, as research teams might be forced to pivot to unrelated areas. His comments indicate a growing concern that the short-sighted cuts to funding may stall crucial advancements in the realm of HIV vaccine development. Research on effective vaccines has seen promising leads in recent years, and the abandonment of these initiatives could have detrimental consequences in the public health landscape.

No. Key Points
1 FDA approved lenacapavir as a bi-annual injection for HIV prevention.
2 99.9% of participants in clinical trials remained HIV negative after taking the drug.
3 31,800 new HIV infections were reported in the U.S. in 2022.
4 Concerns grow regarding cuts to HIV vaccine research funding.
5 Experts emphasize the need to continue pursuing HIV vaccine development.

Summary

The FDA’s approval of lenacapavir marks a pivotal moment in the ongoing battle against HIV. With its high efficacy rate and the potential to curb new infections, it represents a significant advancement in treatment options. However, the concurrent threats to vaccine research funding pose serious challenges that could limit future progress. The dual-track approach of treatment and vaccine development remains essential in efforts to end the HIV epidemic once and for all.

Frequently Asked Questions

Question: What is lenacapavir?

Lenacapavir, marketed as Yeztugo, is a prescription medication approved by the FDA for the prevention of HIV, administered as a bi-annual injection. Clinical trials show it has a 99.9% effectiveness rate.

Question: What are the implications of the FDA’s approval of lenacapavir?

The approval is seen as a monumental step in HIV prevention, offering a new option for individuals at risk of infection and potentially reducing new case rates significantly.

Question: Why is there concern about cuts to vaccine research funding?

Cuts to vaccine research funding jeopardize ongoing studies and discourage advancements in developing a vaccine to combat HIV, which many experts believe is crucial alongside existing treatment methods.

approves Banking Budgeting Consumer Finance Credit Cards Debt Management drug Economic Indicators Economic Trends Entrepreneurship FDA Financial Literacy Financial News Financial Planning HIV Injection Investing Lenacapavir Market Analysis Money Tips Personal Finance Prevention Retirement Saving Side Hustles Stock Market TwiceYearly Wealth Management
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Money Watch

Domino’s Unveils First Major Redesign in 13 Years

5 Mins Read
Money Watch

Excitement and Concerns Surround OpenAI’s Sora 2 and New AI Video Tools

7 Mins Read
Money Watch

Trump Administration Considers $10 Billion Aid Package for Farmers

5 Mins Read
Money Watch

Rising Paycheck-to-Paycheck Living Threatens Retirement for Many Americans

6 Mins Read
Money Watch

Surge in Long-Term Unemployment Raises Concerns Across Multiple Platforms

6 Mins Read
Money Watch

Key Clarifications on Back Pay Eligibility Following Government Shutdown

6 Mins Read
Journalism Under Siege
Editors Picks

U.N. Rejects U.S. Resolution to End Ukraine War Citing Missing Russian Aggression Acknowledgment

February 24, 2025

Musk’s DOGE Cuts Could Shield Tesla and Neuralink from Fines: Memo

April 28, 2025

Chinese Couple Faces Charges for Smuggling Biological Pathogen into U.S.

June 3, 2025

Trump Criticizes Rep. Al Green as ‘Embarrassment’ to Democrats, Calls for IQ Test

March 6, 2025

Trump Administration Appeals to Supreme Court on Foreign Aid Freeze Issue

February 26, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
Go to mobile version